Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV
This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism.
Authors
- Tangkai Qi (ORCID: https://orcid.org/0000-0002-3771-2488)
- Renfang Zhang
- Jiangrong Wang (ORCID: https://orcid.org/0000-0002-0001-503X)
- Yinzhong Shen (ORCID: https://orcid.org/0000-0002-7604-5139)
- Junyang Yang
- Li Liu (ORCID: https://orcid.org/0000-0003-2314-8756)
- Jun Chen (ORCID: https://orcid.org/0000-0002-3439-0495)
- Jianjun Sun (ORCID: https://orcid.org/0000-0001-5780-5334)
- Lin Wang (ORCID: https://orcid.org/0000-0002-2610-695X)
- Zhenyan Wang
- Yang Tang (ORCID: https://orcid.org/0000-0002-4515-1748)
- Wei Song (ORCID: https://orcid.org/0009-0000-5612-7228)
- Shuibao Xu
Institutions
- Shanghai Public Health Clinical Center (CN)
Publication Details
- Journal
- AIDS Research and Therapy
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1186/s12981-024-00680-x
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00